ClinicalTrials.gg
Not yet recruitingNCT07828353Updated Sep 24, 2026

A Clinical Study of REGEND001 for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)

A Phase 3 interventional study of Placebo and REGEND001 in COPD (Chronic Obstructive Pulmonary Disease), sponsored by Regend Therapeutics. Not yet recruiting at 1 site in China. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by Regend Therapeutics · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 404 studies in Pulmonary Disease, Chronic Obstructive with a site in China — 108 open to participants now, 125 under way, 15 of them phase 3. Pulmonary Disease, Chronic Obstructive · China.

Planned enrollment
168th of 286
102 · median 155
Started
2026
with 33 others
Phase 3
63 of 404
13 open now
Primary completion
2028-09
later than 101 of 124 live
Registered
401st of 404
by date

Among the 404 studies in Pulmonary Disease, Chronic Obstructive with a site in China, this one is the 168th largest by planned enrollment of the 286 interventional ones that give a count, is one of 34 that started in 2026, is one of 63 in phase 3, reaches primary completion later than 101 of the 124 other live ones, and was the 401st registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

108 of the 404 studies in Pulmonary Disease, Chronic Obstructive with a site in China are open now. Recruiting first, the newest first:

103 more — sign in →

All 108 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 404 studies in Pulmonary Disease, Chronic Obstructive with a site in China, or all of them as a file.
02

Study summary

Chronic obstructive pulmonary disease (COPD) is a common, progressive, and heterogeneous respiratory disorder. It is associated with substantial morbidity and mortality worldwide, leading to progressive decline in lung function, impaired quality of life, and a significant healthcare burden. REGEND001, made from airway basal stem cells with ability to regenerate lung tissue, is promising to COPD treatment. In this study, a multicenter, randomized, blinded, placebo-parallel-controlled trial is performed to verify the efficacy and safety of REGEND001 in treatment of COPD patients with emphysema.

03

Conditions studied

  • COPD (Chronic Obstructive Pulmonary Disease)

Keywords

  • airway basal stem cells
  • regenerative medicine
  • COPD
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, aged 40-75 years;
  • Diagnosed with ;
  • Post-bronchodilator /FVC \<0.7
  • Emphysematous lesions demonstrated by HRCT;
  • -corrected DLCO%predicted ≥20% and \<70%;
  • Post-bronchodilator FEV1%predicted ≤80%;
  • COPD Assessment Test (CAT) score ≥3;

Exclusion criteria

Exclusion Criteria:

  • History of ≥2 exacerbations leading to hospitalization within 1 year prior to screening, or a COPD exacerbation leading to hospitalization within 2 months prior to screening;
  • Current or previous history of ;
  • An assessed of \<1 year;
  • Respiratory tract infection or systemic infection requiring treatment, or severe localized infection within 4 weeks prior to screening;
  • History of invasive or non-invasive mechanical ventilation within 4 weeks prior to screening;
  • Diagnosis of pneumonia within 3 months prior to screening;
  • Abnormal coagulation function affecting the safety of fiberoptic bronchoscopy procedures at screening;
  • Subjects requiring long-term maintenance anticoagulant therapy or antiplatelet therapy, who are unable to discontinue such medications for at least 1 week prior to cell collection and cell infusion;
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
102 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Participants randomized to the Placebo Comparator arm will receive a single administration of placebo.

    Biological: Placebo

  • Experimental
    REGEND001

    Participants randomized to the experimental arm will receive a single administration of REGEND001.

    Biological: REGEND001

Interventions

  • BiologicalPlacebo

    Participants enrolled will have a bronchoscopy with brushing for cell collection, followed by a single adiministratoin of placebo via bronchoscopy and 1 year of follow-up.

  • BiologicalREGEND001

    Participants enrolled will have a bronchoscopy with brushing for cell collection, followed by a single adiministratoin of REGEND001 via bronchoscopy and 1 year of follow-up.

06

What researchers measure

Primary outcomes

  1. Change from baseline in the measured Diffusing Capacity of the Lung for Carbon Monoxide (DLCO)

    The change from baseline in measured DLCO is defined as the difference between the absolute measured DLCO value at baseline and that measured at the assessment time point after treatment.

    Time frame: Week 52 after treatment

Secondary outcomes

  1. Change from baseline in COPD Assessment Test (CAT) score

    The COPD Assessment Test (CAT) is an 8-item questionnaire used to assess the impact of COPD on health status. The total score ranges from 0 to 40, with higher scores indicating a greater impact of COPD and worse health status. Change from baseline is calculated as the post-treatment CAT score minus the baseline CAT score.

    Time frame: Week 12, 24 and 52 after treatment

  2. Proportion of subjects with a ≥2-point improvement or worsening from baseline in CAT score

    Minimal clinically important difference for CAT is recognized as 2 points.

    Time frame: Week 12, 24 and 52 after treatment

  3. Change from baseline in DLCO

    DLCO is assessed by absolute measured value, hemoglobin (Hb)-corrected measured/predicted ratios and corresponding area under curve (AUC).

    Time frame: Week 12, 24 and 52 after treatment

  4. Proportion of subjects with a ≥11% relative improvement or worsening from baseline in absolute measured DLCO

    Minimal clinically important difference (MCID) of DLCO is recognized as 11%.

    Time frame: Week 12, 24 and 52 after treatment

  5. Change from baseline in alveolar volume (VA)

    VA is assessed by measured values, measured/predicted ratio and corresponding area under curve (AUC).

    Time frame: Week 12, 24 and 52 after treatment

  6. Change from baseline in forced expiratory volume in the first second (FEV1) post-bronchodilator

    FEV1 is assessed by measured value, measured/predicted ratio and corresponding area under curve (AUC).

    Time frame: Week 12, 24 and 52 after treatment

  7. Change from baseline in 6-minute walk distance (6MWD)

    6MWD is assessed by the measured value and corresponding area under curve

    Time frame: Week 12, 24 and 52 after treatment

  8. Proportion of subjects with a ≥30-meter change from baseline in 6MWD

    Minimal clinically important difference (MCID) of 6MWD is recognized as 30 meters.

    Time frame: Week 12, 24 and 52 after treatment

  9. Change from baseline in St. George's Respiratory Questionnaire for COPD (SGRQ-C) score

    The St. George's Respiratory Questionnaire for COPD (SGRQ-C) is a validated disease-specific patient-reported outcome measure used to assess the impact of COPD on patients' health status and quality of life. Total score, ranged from 0 to 100, is the sum of points from all items. A higher value represents a worse outcome.

    Time frame: Week 12, 24 and 52 after treatment

  10. Proportion of subjects with a ≥4-point improvement or worsening from baseline in SGRQ-C score

    Minimal clinically important difference for SGRQ is recognized as 4 points.

    Time frame: Week 12, 24 and 52 after treatment

  11. Annualized rate of COPD exacerbations (AECOPD), adjusted for prior exacerbation history and baseline characteristics

    The annualized rate of COPD exacerbations (AECOPD), adjusted for prior exacerbation history and baseline characteristics, represents the adjusted frequency of acute exacerbations of COPD over the assessment period.

    Time frame: Week 52 after treatment

  12. Change from baseline in arterial blood gas parameters

    The change from baseline in arterial blood gas parameters reflects changes in gas exchange function and respiratory status over the assessment period.

    Time frame: Week 52 after treatment

  13. Change from baseline in HRCT images

    HRCT images are quantitatively analyzed using dedicated software to measure emphysema volume (mL) and functional lung volume (mL).

    Time frame: Week 52 after treatment

  14. Adverse Event

    An adverse event (AE) is any untoward medical occurrence in a subject who has received a study intervention, regardless of whether or not it is considered related to the intervention.

    Time frame: Hour 24, Week 12, 24 and 52 after treatment

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Sep 2028, 23 months later.

Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's planned 23 months is above that.

Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2026
First posted
Sep 18, 2026
StartEst.
Oct 2026
Primary completionEst.
Sep 2028
CompletionEst.
Sep 2028
Last update
Sep 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07828353
Lead sponsor
Regend Therapeutics
Responsible party
Sponsor
First posted
Sep 18, 2026
Start date
Oct 2026 (estimated)
Primary completion
Sep 2028 (estimated)
Completion
Sep 2028 (estimated)
Last update
Sep 24, 2026

Study contacts

Shiyue Li, Professor and Chief Physician
Contact
lishiyue@188.com
86-20-83062114

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: REGEND001

Start the discussion